Cargando…

NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome

PURPOSE: To determine whether levels of nerve growth factor (NGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to objectively assess overactive bladder syndrome (OAB) treatment outcome and to evaluate the effects of fixed-dose fesoterodine on OAB symptoms. MATE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Soo Rim, Moon, Yeo Jung, Kim, Sei Kwang, Bai, Sang Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276757/ https://www.ncbi.nlm.nih.gov/pubmed/25510766 http://dx.doi.org/10.3349/ymj.2015.56.1.204

Ejemplares similares

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
por: Peral, Carmen, et al.
Publicado: (2016)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Changes in Sexual Function and Comparison of Questionnaires Following Surgery for Pelvic Organ Prolapse
por: Kim, Soo Rim, et al.
Publicado: (2014)

The significance and factors related to bladder outlet obstruction in pelvic floor dysfunction in preoperative urodynamic studies: A retrospective cohort study
por: Lee, Yoo Jin, et al.
Publicado: (2014)

Identification of the Cancer Cell Proliferation and Survival Functions of proHB-EGF by Using an Anti-HB-EGF Antibody
por: Sato, Shuji, et al.
Publicado: (2013)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma
por: Al-Ghazzawi, Karim, et al.
Publicado: (2023)

APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis
por: Zhang, Chen-Ou, et al.
Publicado: (2005)

Efficacy and Safety of Propiverine in Children with Overactive Bladder
por: Kim, Woo Jung, et al.
Publicado: (2012)

A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF
por: Sato, Shuji, et al.
Publicado: (2012)

Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate
por: Lee, Hong-Goo, et al.
Publicado: (2019)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Urinary biomarkers of overactive bladder
por: Tian, Xiao-Jun, et al.
Publicado: (2019)

Correlation of IL-1 and HB-EGF with endometrial receptivity
por: Wang, Hui, et al.
Publicado: (2018)

Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers
por: Iwamoto, Ryo, et al.
Publicado: (2016)

Analysis of the Risk Factors for Overactive Bladder on the Basis of a Survey in the Community
por: Jo, Jung Ki, et al.
Publicado: (2012)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

An unanticipated discourse of HB-EGF with VANGL2 signaling during embryo implantation
por: Kim, Yeon Sun, et al.
Publicado: (2023)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Comparison of midurethral sling outcomes with and without concomitant prolapse repair
por: Han, E Jung, et al.
Publicado: (2014)

Helicobacter pylori-Induced HB-EGF Upregulates Gastrin Expression via the EGF Receptor, C-Raf, Mek1, and Erk2 in the MAPK Pathway
por: Gunawardhana, Niluka, et al.
Publicado: (2018)

Excess HB-EGF, which promotes VEGF signaling, leads to hydrocephalus
por: Shim, Joon W., et al.
Publicado: (2016)

HB-EGF Ameliorates Oxidative Stress-Mediated Uterine Decidualization Damage
por: Yu, Hai-Fan, et al.
Publicado: (2019)

The Impact of Overactive Bladder on Health-Related Quality of Life, Sexual Life and Psychological Health in Korea
por: Yoo, Eun Sang, et al.
Publicado: (2011)

Correlation of Male Overactive Bladder with Intravesical Prostatic Protrusion
por: Kim, Ki Hong, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j1bil9jhjshqn8uo7vllqnsvc6